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ABSTRACT
INTRODUCTION:Guillain-Barre syndrome (GBS) is a polyradiculoneuropathy characterized by a rapidly progressive 
bilateral paresis of the limbs. Nadir is typically reached within a number of days or weeks, followed by a recovery that 
is generally much slower and often incomplete. Guillain-Barre syndrome is usually preceded by infection or other 
immune stimulation that induces an aberrant autoimmune response targeting peripheral nerves and their spinal 
roots.IVIG and Plasmapheresis are used first line treatments in GBS treatment. For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and IVIG efficacy are needed. Aim of this study is to determine serum 
albumin as an independent biomarker for clinical outcome in plasmapheresis treated-GBS patients.
MATERIAL AND METHODS: This was a descriptive case study conducted in Neurology Department ShaheedZulfiqar Ali 
Bhutto Medical University Islamabad for the period of six months from July 2017 to December 2017. Serum albumin 
levels were determined in 70 patients with GBS. Patients were assigned into two groups. One with low albumin level 
(26 patients, 37.1 %) and other with normal albumin level (44 patients, 62.9% ). Every patient underwent same 
number of sessions of plasmapheresis and assessed clinically by using GBS disability score and Medical Research 
Council (MRC) sum score for a follow up period of 6 months. 
RESULTS:  Out of 26 patients with low albumin level 7 patients, 26.9%,  had good outcome and 19 patients,73.1%, 
had poor outcome i.e had significant disability at 6 months follow up with GBS disability scale score of 2 or more.
Out of 44  patients who had normal albumin level 25 patients,45.7%, showed good clinical outcome and 19 patients, 
54.3%, showed poor clinical outcome on the basis of GBS disability score and MRC sum score after a period of 6 
months. P value was 0.015 and was significant in that higher the albumin levels will be, more chances of having good 
prognosis.
O R I G I N A L  A R T I C L E
CONCLUSION: This study determined albumin level as 
an independent factor for short and long term clinical 
outcome and prognosis in Guillain Barre Syndrome 
patients treated with plasmapheresis. However, there is 
need of prospective studies that should confirm the 
findings of this study of albumin level as a prognostic 
biomarker for GBS patient.
Guillain-Barre syndrome (GBS) is a 
polyradiculoneuropathy characterized by a rapidly 
progressive bilateral paresis of the limbs. Nadir is 
typically reached within a number of days or weeks, 
followed by a recovery that is generally much slower 
and often incomplete.[1]
The clinical course of GBS follows a typical pattern that 
can be readily divided into its constituent phases and 
components (figure-1).[2] Demyelinating and axonal 
forms of the syndrome occur in varying proportions 
across different geographical regions.[3]
Guillain-Barre syndrome is usually preceded by 
infection or other immune stimulation that induces an 
aberrant autoimmune response targeting peripheral 
nerves and their spinal roots.[4,5] Despite the positive 
effect of intravenous immunoglobulin (IVIG) or plasma 
exchange (PE), about 20% of the patients are unable to 
walk unaided (‘severely affected patients’) and remain 
unable to do so after six months. Moreover, many 
patients remain otherwise disabled or severely fatigued. 
Even 3–6 years after onset, GBS had great impact on 
social life and the ability to perform activities.[6,7] Still, 
the reasons why some patients respond poorly to IVIG 
therapy are unknown, and there is an urgent need to 
find a biomarker that, preferably, can be determined 
within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
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Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
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Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
0 3P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S
Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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0    A healthy state
1    Minor symptoms and capable of running
2    Able to walk 10 meter or more without assistance but unable to run 
3    Able to walk 10 meter across an open space with help    
4    Bedridden or chairbound
5    Requiring assisted ventilation for at least part of the day 
6    Death
0   No visible contraction
1   Visible contraction without movement of the limb
2   Active movement of the limb but not against the gravity
3   Active movement against gravity over (almost) the full range
4   Active movement against gravity and resistance
5   Normal power
Albumin Range Low
Normal
Total
12
33
45
26.7%
73.3%
100.0%
Gender
Male
Count Column N %
14
11
25
56.0%
44.0%
100.0%
Count Column N %
26
44
70
37.1%
62.9%
100.0%
Count Column N %
Female Total
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within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
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Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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within the first 2 weeks of onset. Such a biomarker 
would allow a more personalized approach to monitor 
treatment efficacy and anticipate outcome.[8,9] 
Existing prognostic models are based on clinical 
features, including the extent of muscle weakness and 
demographic factors, but previous studies failed to 
identify a serologic biomarker to enhance these 
models.[10] For better assessment of treatment 
response, biomarkers reflecting Plasmapheresis and 
IVIG efficacy are needed. The approach and the 
measurement of such biomarkers should be easy, 
accessible, straight forward and accurate, and 
preferably it should be available with routine diagnostic 
procedures.
Serum albumin is a protein that binds to the neonatal 
Fc receptor (FcRn), which transports it back into the 
circulation and its level is reduced after high-dose IVIG 
therapy in diseases other than GBS.[11]
Furthermore, serum albumin is identified as an 
independent factor associated with outcome in 
amyotrophic lateral sclerosis and failure of IVIG therapy 
in Kawasaki disease.[12,13] Therefore, serum albumin 
is an interesting alternative to IgG as a biomarker for 
assessing the severity of GBS, fitting the profile of a 
routinely measured protein already established as a 
prognostic marker in numerous pathologic 
conditions.[14] Although few studies on serum albumin 
association with intravenous immunoglobulins-treated 
guillain barre syndrome are available but no study has 
been done on serum albumin association with outcome 
in Plasmapheresis-treated GBS in Pakistan. 
In this study, we aimed to find out whether serum 
albumin levels can serve as a prognostic marker in 
patients with GBS treated with plasmapheresis. We 
checked the serumalbumin levels in GBS patients after 
their initial presentation i.e before plasmapheresis 
along with routine investigations. Finally, we analyzed 
whether circulatory albumin levels were associated with 
disease severity and outcome.
MATERIALS AND METHODS:
This was a descriptive case study conducted in 
Neurology Department Shaheed Zulfiqar Ali Bhutto 
Medical University Islamabad for the period of six 
months from July 2017 to December 2017 after 
getting permission from ethical committee of the 
hospital and university. A total of 70 patients of Guillain 
Barre Syndrome were enrolled using non probability 
consecutive sampling. Sample size was calculated 
using WHO sample size calculator. An informed written 
consent was taken from all patients. All patients of both 
genders of age 13 to 75 years with Guillain Barre 
Syndrome were enrolled in this study. GBS was 
diagnosed on the basis of clinical and 
electrophysiological criteria. The diagnostic criteria for 
Guillain Barre Syndrome was defined from National 
Institute of neurological Disorders and Stroke 
(NINDS).[15]
For the AXONAL variant of GBS criteria was set not 
having demyelination and low amplitude of compound 
muscle action potential (CMAP) in two or more motor 
nerves in AMAN. For AMSAN no demyelination, low 
amplitude of compound muscle action potential 
(CMAP) in two or more nerves as well as low sensory 
nerve action potentials (SNAP) in two or more nerves. 
For Miller Fisher variant of GBS reduced or absent 
SNAPs with evidence of involvement of motor nerves 
and no demyelination.[16]
Sensory manifestations were determined clinically if 
patients complained of muscle pain and aches, 
paresthesias (burning, tingling, pins and needles 
sensations), numbness in fingers and toes, impaired 
pin prick, joint position and vibration sensations. 
Respiratory distress was defined as if patient has single 
breath count less than twenty.[17]
Patients were divided into two groups i.e patient with 
low serum albumin levels (3.5mg/dl or below) and 
patient with normal serum albumin level (3.5-5.5 
mg/dl). All 70 patients in both the groups received 
same number of plasmapheresis. Serum albumin levels 
were checked before starting plasmapheresis. Patients 
in both the groups were followed for the period of 6 
months and assessed for clinical outcome keeping in 
mind the association of low and normal albumin levels 
using Medical Research Council(MRC) sum score, it is 
a score of six muscles group including shoulder 
abduction, elbow flexors, wrist extensors, hip flexors, 
knee extensors and foot dorsiflexors on both sides 
ranging from 60 (normal) to 0 (quadriplegic), the 
Modified Rankin Scale (MRS) score of individual 
muscle ranges from 0 to 5 as shown in figure-1 and 
GBS disability score ranging from 0 (healthy) to 6 
(deceased) as shown in figure-2. Not being able to walk 
10 meters independently (GBS disability score >2) at 
6 months was regarded as poor outcome. 
To assess the possible influence of serum albumin on 
disease activity and clinical outcome patients were 
followed and assessed at 0, 1, 2, 4 and 26 weeks 
interval and GBS disability and MRS sum score was 
calculated at each stage to determine clinical outcome. 
Data was entered on a standard performa. Data was 
analyzed using SPSS version 17. Mean and standard 
deviations were calculated for numerical variables i.e 
age. Frequencies and percentages were calculated for 
categorical variables (gender, outcome).
Chi square test was used to compare the percentages 
of clinical outcome between two groups. P value of 
<0.05 was taken as significant. 
Figure-1: GBS disability score
Figure-2: Medical Research Council(MRC) sum 
score
RESULTS:
Serum albumin levels were determined in 70 patients 
with GBS with a mean age of 35.3 yeears. Out of 70 
patients 45 were males and 25 were females. Patients 
were assigned into two groups. One with low albumin 
level (26 patients, 37.1 %) and other with normal 
albumin level (44 patients, 62.9% ) as shown in 
figure-3. There was no significant age predilection. 
Albumin levels were obtained on admission. Albumin 
level with respect to age is shown in figure-4. Every 
patient underwent same number of sessions of 
plasmapheresis and assessed clinically by using GBS 
disability score and MRC sum score. Both axonal and 
demyelinating variants of GBS were followed and seen 
for disability. It was noted that the axonal variant of GBS 
showed poor outcome at the end of follow up period of 
6 months.
Figure-3:
Figure-4:
Out of 26 patients with low albumin level 4 patients 
(15.38%) underwent mechanical ventilation due to 
respiratory distress. Out  of 44 patients with normal 
albumin 3 patients (6.81%) needed the mechanical 
ventilation.
Out of 26 patients with low albumin level 7 patients, 
26.9%,  had good outcome and 19 
patients,73.1%,had poor outcome i.e had significant 
disability at 6 months follow up with GBS disability scale 
score of 2 or more.
Out of 44  patients who had normal albumin level 25 
patients,45.7%, showed good clinical outcome and 19 
patients, 54.3%, showed poor clinical outcome on the 
basis of GBS disability score and MRC sum score after 
a period of 6 months. These results are showed in 
figure-5.
P-Value was 0.015 and was significant.
Figure-5:
DISCUSSION:
A positive correlation was observed between serum 
albumin level and clinical outcome of GBS. With normal 
albumin level good clinical outcome and low albumin 
level poor clinical outcome was observed at the end of 
follow up. In addition, patients not requiring mechanical 
ventilation also had poor clinical outcome depending 
upon low albumin levels. Patients who maintained 
albumin level in normal range showed good clinical 
improvement indicating albumin level as an 
independent prognostic factor in GBS. The results of our 
study are comparable with an international study, 
Willem-Jan R.et al[18], that established an association 
of low albumin level with poor outcome in Intravenous 
Immunoglobulins treated Guillain Barre Syndrome.
The preferable treatment for Guillain Barre Syndrome is 
Intravenous Immunoglobulins but in resource limited 
countries like Pakistan affordability is a major issue and 
plasmapheresis is being done regularly for GBS patients 
because of its cost effectiveness and easy availability of 
the procedures at most of the medical centres in 
Pakistan.
Clinical prognostic models have been developed 
previously to estimate the chance of respiratory failure 
and disability at 1, 3 and 6 months.[19-21]
No prognostic biomarkers are available for GBS, an 
acute and debilitating disease. Biomarkers are of such 
importance they give an early indication of 
clinicaloutcome and for optimal care to provide with.  
The main causes of a reduction in serum albumin are 
increased catabolism, decreased
production, and extravasation attributable to increased 
capillary permeability in the setting of inflammation or 
severe disease.[14,22,23] In patients with Guillain 
Barre Syndrome any of the above cause of low albumin 
level can be found either in isolation or in combination. 
Regarding prognosis and an indicator for good health 
albumin has been explored as a marker in numerous 
diseases.[24]
In a study it was determined that a low serum albumin 
level is a strong marker of poor outcome in the setting 
of acute illness.[25,26]
GBS is an also acute illness and needs a prognostic 
marker to intervene and provide maximum medical care 
so we tried to find out albumin as an independent 
model for clinical outcome in Guillain Barre Syndrome. 
Patients with low albumin levels may also have 
increased need of ventilatory support and decrease 
survival ultimately due to disease progression and 
ventilator associated complications. To prevent such 
morbidities and mortalities prognostic markers for acute 
illnesses like GBS are of utmost importance. A study, 
focusing on ICU and critically ill patients identified 
serum albumin as a biomarker for survival and the need 
for mechanical ventilation.[27-29]
Determining the albumin level once and at initial stage 
also has advantage as its level may change with disease 
progression and procedure i.e plasmapheresis, related 
fluctuations of albumin concentrations that may also 
cause expansion of plasma volume and thereby 
reducing the albumin levels.
CONCLUSION:
This study determined albumin level, as a part of 
comprehensive metabolic profile, as an independent 
factor for short and long term clinical outcome and 
prognosis in Guillain Barre Syndrome patients treated 
with plasmapheresis. However, there is need of 
prospective studies that should confirm the findings of 
this study of albumin level as a prognostic biomarker for 
GBS patient.   
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